Myriad Genetics Inc
MYGN Nasdaq· In Vitro & In Vivo Diagnostic Substances
Last close · Oct 26, 2026
$6.02
KIRA · Stoqly’s AI analyst, in plain words
- Myriad Genetics Inc had $825M of revenue in fiscal 2025, down 1.6% on the year before. Over five years, revenue changed +5.2% a year on average.
- Its operating margin was −47.0%, down 32.2 pts: of every 100 in sales, about −47 is left after running the business.
- Myriad Genetics Inc lost $366M in fiscal 2025.
- Myriad Genetics Inc has $29.7M more cash than debt.
Market cap
$571M
P/E
—
Revenue
$825M
Net income
−$366M
Free cash flow
—
Operating margin
−47.0%
Myriad Genetics Inc in 30 seconds · fiscal 2025
Are sales growing?
−1.6%
No. Sales fell 1.6% last year.
Does it make a profit?
−44.4%
No. It lost money last year.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Myriad Genetics Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- MYRIAD GENETICS INC
- CIK
- 0000899923
Myriad Genetics Inc · MYGN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $691M | $678M | $753M | $838M | $825M |
| Revenue growth | 8.1% | −1.8% | 11.0% | 11.2% | −1.6% |
| Gross margin | — | 70.2% | 68.6% | 69.9% | 69.9% |
| Operating margin | −27.6% | −20.7% | −34.2% | −14.7% | −47.0% |
| Net income | −$27.2M | −$112M | −$263M | −$127M | −$366M |
| Net margin | −3.9% | −16.5% | −35.0% | −15.2% | −44.4% |
| Diluted EPS | −$0.35 | −$1.39 | −$3.18 | −$1.41 | −$3.95 |
| Cash | |||||
| Cash from operations | $18.6M | −$106M | −$111M | −$8.7M | $1.8M |
| Capital expenditure | $18.0M | $45.3M | — | — | — |
| Free cash flow | $0.6M | −$152M | — | — | — |
| FCF margin | 0.1% | −22.3% | — | — | — |
| Share buybacks | $0.0M | — | — | — | — |
| Share count change | 5.0% | 3.3% | 2.7% | 9.4% | 2.2% |
| Debt and strength | |||||
| Cash and short-term investments | $339M | $115M | $141M | $102M | $150M |
| Debt incl. finance leases | $0.0M | $0.0M | $38.5M | $39.6M | $120M |
| Shareholders' equity | $968M | $886M | $783M | $701M | $368M |
| Current ratio | 2.4x | 2.0x | 2.0x | 1.8x | 2.5x |
| Interest coverage | −28.9x | −43.9x | −88.8x | −44.1x | −36.9x |
| Returns and quality | |||||
| Return on capital | −23.9% | −14.4% | −29.9% | −15.3% | −90.4% |
| Return on equity | −2.9% | −12.1% | −31.6% | −17.2% | −68.5% |
| Return on tangible equity | −8.4% | −51.1% | −180.0% | −83.5% | −224.5% |
| Piotroski F-score | 5 | 2 | 3 | 4 | 5 |
| Altman Z'' | 2.7 | 1.9 | −0.1 | −0.1 | −5.9 |
Insiders bought, 12 months
$0.7M
3 insiders
Insiders sold, 12 months
$0.1M
1 insider
Of sales under plans
100%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Myriad Genetics Inc · MYGN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.02 a share, the company is worth $571M.
Source: SEC EDGAR XBRL filings (CIK 0000899923). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.